已發表論文：（*為通訊作者） (1) LU L, SHEN L, WU Z, SHI Y, HOU P, XUE Z, LIN C, CHEN X*. Trajectories of serum α-fetoprotein and intermediate-stage hepatocellular carcinoma outcomes after transarterial chemoembolization: A longitudinal, retrospective, multicentre, cohort study. EClinicalMedicine [J].2022 Apr 16;47:101391.(影響因子17.033) (2) Lin Y, Yu X, Lu L, Chen H, Wu J, Chen Y, Lin Q, Wang X, Chen X, Chen X*. Age is a significant biomarker for the selection of neoadjuvant chemotherapy plus radiotherapy versus concurrent chemoradiotherapy in patients with advanced nasopharyngeal carcinoma. Cancer Biomark. 2023 Mar 7.(影響因子3.828) (3) SU Z, LU L, CHEN F, CHEN J, CHEN X*. Gut Microbiota and Sunitinib-Induced Diarrhea in Metastatic Renal Cell Carcinoma: A Pilot Study. Cancer Manag Res [J]2021 Nov 20;13:8663-8672.(影響因子3.602) (4) LU L, ZHENG P, WU Z, CHEN X*. Hepatic Resection Versus Transarterial Chemoembolization for Intermediate-Stage Hepatocellular Carcinoma: A Cohort Study. Front Oncol [J].2021 Oct 27;11:618937.(影響因子 5.738) (5) Wang X, Wang Z, Chen Y, Lin Q, Chen H, Lin Y, Lu L, Zheng P, Chen X*. Impact of prior cancer on the overall survival of patients with nasopharyngeal carcinoma. Am J Otolaryngol[J]. 2022 Jan-Feb;43(1): 103235. (影響因子2.873) (6) Lin Q, Lu L, Wang X, Lin Y, Chen Y, Chen H, Chen S, Lin S, Zhang Y, Zheng P, Chen X*. Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus neoadjuvant chemotherapy plus concurrent chemoradiotherapy for ascending or descending types of nasopharyngeal carcinoma: A retrospective study[J]. Am J Otolaryngol. 2022 Jan-Feb;43(1):103193.(影響因子2.873) (7) LU L, SU Z, ZHENG P, WU Z, ZHANG Y, HE H, LIU J, LIN S, CHEN X*. Association between platelet count and hepatocellular carcinoma overall survival: a large retrospective cohort study. BMJ Open [J]2020 Nov 6;10(11):e038172.(影響因子3.006) (8) LU L, ZHANG Y, ZHENG P, WU Z, WANG X, CHEN Y, CHEN X*. Elevated Platelet Count is Associated with Poor Survival After Transarterial Chemoembolization Treatment in Patients with Hepatocellular Carcinoma: A Cohort Study. J Hepatocell Carcinoma [J], 2020 Oct15;7:191-199.（影響因子4.962） (9) WANG X, WU S, CHEN Y, SHAO E, ZHUANG T, LU L, CHEN X*. Fatal Adverse Events Associated With Programmed Cell Death Ligand 1 Inhibitors: A Systematic Review and Meta-Analysis. Front Pharmacol [J],2020 Jan 31;11:5.(影響因子5.988) (10) Zheng P, Chen X, Xie J, Chen X, Lin S, Ye L, Chen L, Lin J, Yu X, Zheng M. Capn4 is induced by and required for LMP1 promotion of nasopharyngeal carcinoma metastasis through ERK/AP-1 signaling. Cancer Sci. 2019 Nov 5. (影響因子6.518) (11) Lu L, Zhuang T, Shao E, Liu Y, He H, Shu Z, Huang Y, Yao Y, Lin S, Lin S, Chen X, Chen X*. Association of antibiotic exposure with the mortality in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy: A hospital-based retrospective cohort study. PLoS One. 2019 Sep 10;14(9):e0221964. (影響因子3.752) (12) Huang Y, Zheng J, Tan T, Song L, Huang S, Zhang Y, Lin L, Liu J, Zheng P, Chen X*, Chen X, Ouyang X: BTG1 low expression in pancreatic ductal adenocarcinoma is associated with a poorer prognosis. Int. J. Biol. Markers, 2017. (影響因子3.248) (13) Yu R, Li C, Lin X, Chen Q, Li J, Song L, Lin L, Liu J, Zhang Y, Kong W, Ouyang X, Chen X*: Clinicopathologic features and prognostic implications of MYBL2 protein expression in pancreatic ductal adenocarcinoma..Pathol. Res. Pract., 2017, 213(8): 964-968. (影響因子3.309) (14) Yin Y, Zhu X, Huang S, Zheng J, Zhang M, Kong W, Chen Q, Zhang Y, Chen X* Lin K, Ouyang X: Expression and clinical significance of placenta-specific 1 in pancreatic ductal adenocarcinoma. Tumour Biol., 2017, 39(6): 1010428317699131. (15) HUANG S, CHEN X, ZHENG J, HUANG Y, SONG L, YIN Y, XIONG J. Low SIRT3 expression contributes to tumor progression, development and poor prognosis in human pancreatic carcinoma. Pathol Res Pract [J], 2017 Nov;213(11):1419-1423.（影響因子3.309） (16) Zheng J, Huang S, Huang Y, Song L, Yin Y, Kong W, Chen X*, Ouyang X: Expression and prognosis value of SHP2 in patients with pancreatic ductal adenocarcinoma. Tumour Biol 2016; 37: 7853-7859. (17) Huang S, Zheng J, Huang Y, Song L, Yin Y, Ou D, He S, Chen X*, Ouyang X*: Impact of S100A4 expression on clinicopathological characteristics and prognosis in pancreatic cancer: A Meta-Analysis. DIS MARKERS 2016;2016:8137378. (影響因子3.464) (18) ZHENG P C, CHEN X, ZHU H W, ZHENG W, MAO L H, LIN C, LIU J N, ZHENG M. Capn4 is a marker of poor clinical outcomes and promotes nasopharyngeal carcinoma metastasis via nuclear factor-κB-induced matrix metalloproteinase 2 expression. Cancer Sci [J], 2014 Jun;105(6):630-8.（影響因子6.518） (19) Chen X*, Zheng P, Xue Z, Li J, Wang W, Chen X, Xie F, Yu Z, Ouyang X *. CacyBP/SIP enhances multidrug resistance of pancreatic cancer cells by regulation of P-gp and Bcl-2. Apoptosis. 2013 Jul; 18(7):861-9. (影響因子5.561) (20) Chen X*, Li X, Chen J, Zheng P, Huang S, Ouyang X*. Over-expression of CIAPIN1 inhibited pancreatic cancer cell proliferation and was associated with good prognosis in pancreatic cancer. Cancer Gene Ther. 2012 Aug; 19(8):538-44. (影響因子5.854) (21) Chen X, Mo P, Li X, Zheng P, Zhao L, Xue Z, Ren G, Han G, Wang X, Fan D*. CacyBP/SIP protein promotes proliferation and G1/S transition of human pancreatic cancer cells. Mol Carcinog. 2011 Oct; 50(10):804-10. (影響因子5.139) (22) Chen X, Han G, Zhai H, Zhang F, Wang J, Li X, Huang S, Wang X, Fan D. Expression and Clinical Significance of CacyBP/SIP in Pancreatic Cancer. Pancreatology. 2008; 8(4-5):470–7. (影響因子3.977)
|
